Low-Molecular-Weight Heparin for the Prevention of Placenta-mediated Pregnancy Complications

Clinical Obstetrics and Gynecology

Volumn 60, Issue 1, 2017, Pages 153-160

  Haddad, Bassam ^a   Lecarpentier, Edouard ^a   Touboul, Cyril ^a   Sibai, Baha M ^b  

^a UNIVERSITÉ PARIS EST CRÉTEIL   (France)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

low molecular weight heparin; placenta mediated complications; preeclampsia; prevention

Indexed keywords

ACETYLSALICYLIC ACID; DALTEPARIN; ENOXAPARIN; FOLIC ACID; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; ANTICOAGULANT AGENT;

ANTICOAGULATION; CLINICAL RESEARCH; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; HELLP SYNDROME; HIGH RISK PATIENT; HUMAN; MULTICENTER STUDY (TOPIC); PLACENTA; PREECLAMPSIA; PREGNANCY; PREGNANCY COMPLICATION; PREGNANCY OUTCOME; PREGNANT WOMAN; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SMALL FOR DATE INFANT; THROMBOPHILIA; THROMBOSIS PREVENTION; FEMALE; PLACENTA DISORDER;

ANTICOAGULANTS; FEMALE; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; PLACENTA; PLACENTA DISEASES; PRE-ECLAMPSIA; PREGNANCY; PREGNANCY COMPLICATIONS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 85007168430     PISSN: 00099201     EISSN: 15325520     Source Type: Journal    
DOI: 10.1097/GRF.0000000000000252     Document Type: Review

References (38)

1. Report of the National High Blood Pressure Education Program. Working group report on high blood pressure in pregnancy. Am J Obstet Gynecol. 2000;183:S1-S22.
2. Sibai B, Dekker G, Kupferminc M. Preeclampsia. Lancet. 2005;365:785-799.
3. Caritis S, Sibai B, Hauth J, et al. Low-dose aspirin to prevent preeclampsia in women at high risk. N Engl J Med. 1998;338:701-705.
4. Hnat MD, Sibai BM, Caritis S, et al. Perinatal outcome in women with recurrent preeclampsia compared with women who develop preeclampsia as nulliparous. Am J Obstet Gynecol. 2002;186:422-426.
5. Sibai BM. Chronic hypertension in pregnancy. Obstet Gynecol. 2002;100:369-377.
6. Sibai BM, Hauth J, Caritis S, et al. Hypertensive disorders in twin versus singleton gestations. Am J Obstet Gynecol. 2000;182:938-942.
7. Wen SW, Demissie K, Yang Q, et al. Maternal morbidity and obstetric complications in triplet pregnancies and quadruplet and higher-order multiple pregnancies. Am J Obstet Gynecol. 2004;191:254-258.
8. Haddad B, Deis S, Goffinet F, et al. Maternal and perinatal outcomes during expectant management of 239 severe preeclamptic women between 24 and 33 weeks' gestation. Am J Obstet Gynecol. 2004;190:1590-1595.
9. Askie LM, Duley L, Henderson-Smart DJ, et al. PARIS Collaborative Group. Antiplatelet agents for prevention of pre-eclampsia: a meta-analysis of individual patient data. Lancet. 2007;369: 1791-1798.
10. Rumbold AR, Crowther CA, Haslam RR, et al. Vitamins C and E and the risks of preeclampsia and perinatal complications. N Engl J Med. 2006;354:1796-1806.
11. Poston L, Briley AL, Seed PT, et al. Vitamin C and vitamin E in pregnant women at risk for preeclampsia (VIP trial): randomised placebocontrolled trial. Lancet. 2006;367:1145-1154.
12. Mousa HA, Alfirevic Z. Do placental lesions reflect thrombophilia state in women with adverse pregnancy outcome? Hum Reprod. 2000;15: 1830-1833.
13. Rodger MA, Carrier M, Le Gal G, et al. Metaanalysis of low-molecular-weight heparin to prevent recurrent placenta-mediated pregnancy complications. Blood. 2014;123:822-828.
14. Ferrazzi E, Bulfamante G, Mezzopane R, et al. Uterine Doppler velocimetry and placental hypoxic-ischemic lesion in pregnancies with fetal intrauterine growth restriction. Placenta. 1999;20:389-394.
15. Franco C, Walker M, Robertson J, et al. Placental infarction and thrombophilia. Obstet Gynecol. 2011;117:929-934.
16. Baldus S, Rudolph V, Roiss M, et al. Heparins increase endothelial nitric oxide bioavailability by liberating vessel-immobilized myeloperoxidase. Circulation. 2006;113:1871-1878.
17. Tasatargil A, Ogutman C, Golbasi I, et al. Comparison of the vasodilatory effect of nadroparin, enoxaparin, dalteparin, and unfractioned heparin in human internal mammary artery. J Cardiovasc Pharmacol. 2005;45:550-554.
18. Georgescu A, Popov D, Capraru M, et al. Enoxaparin-a low molecular weight heparin, restores the altered vascular reactivity of resistance arteries in aged and aged-diabetic hamsters. Vascul Pharmacol. 2003;40:167-174.
19. Georgescu A, Alexandru N, Nemecz M, et al. Enoxaparin reduces adrenergic contraction of resistance arterioles in aging and in aging associated with diabetes via engagement of MAP kinase pathway. Blood Coagul Fibrinolysis. 2011;22:310-316.
20. Yokokawa K, Tahara H, Kohno M, et al. Heparin regulates endothelin production through endothelium-derived nitric oxide in human endothelial cells. J Clin Invest. 1993;92:2080-2085.
21. Li Y, Wu Y, Gong X, et al. Low molecular weight heparin decreases the permeability of glomerular endothelial cells when exposed to pre-eclampsia serum in vitro. Nephrology (Carlton). 2012;17:754-759.
22. Redman CW, Sacks GP, Sargent IL. Preeclampsia: an excessive maternal inflammatory response to pregnancy. Am J Obstet Gynecol. 1999;180: 499-506.
23. Staff AC, Johnsen GM, Dechend R, et al. Preeclampsia and uteroplacental acute atherosis: immune and inflammatory factors. J Reprod Immunol. 2014;101-102:120-126.
24. Penning M, Chua JS, Van Kooten C, et al. Classical complement pathway activation in the kidneys of women with preeclampsia. Hypertension. 2015;66:117-125.
25. Girardi G, Redecha P, Salmon JE. Heparin prevents antiphospholipid antibody-induced fetal loss by inhibiting complement activation. Nat Med. 2004;10:1222-1226.
26. McLaughlin K, Drewlo S, Parker JD, et al. Current theories on the prevention of severe preeclampsia with low-molecular weight heparin. Hypertension. 2015;66:1098-1103.
27. Brenner B, Hoffman R, Blumenfeld Z, et al. Gestational outcome in thrombophilic women with recurrent pregnancy loss treated by enoxaparin. Thromb Haemost. 2000;83:693-697.
28. Kupferminc MJ, Fait G, Many A, et al. Lowmolecular-weight heparin for the prevention of obstetric complications in women with thrombophilias. Hypertens Pregnancy. 2001;20:35-44.
29. Grandone E, Brancaccio V, Colaizzo D, et al. Preventing adverse obstetric outcomes in women with genetic thrombophilia. Fertil Steril. 2002;78: 371-375.
30. Haddad B, Winer N, Chitrit Y, et al. Prevention of maternal and perinatal complications by enoxaparin in women with previous severe preeclampsia (HEPEPE): an open-label, multicenter, prospective, randomized, controlled trial SMFM, 2016. Am J Obstet Gynecol. 2016;214:S452. LB1.
31. Rodger MA, Hague WM, Kingdom J, et al. Antepartum dalteparin versus no antepartum dalteparin for the prevention of pregnancy complications in pregnant women with thrombophilia (TIPPS): a multinational open-label randomised trial. Lancet. 2014;384:1673-1683.
32. De Vries JIP, Van Pampus MG, Hague WM, et al. The FRUIT Investigators. Low-molecularweight heparin added to aspirin in the prevention of recurrent early-onset pre-eclampsia in women with inheritable thrombophilia: the FRUITRCT. J Thromb Haemost. 2012;10:64-72.
33. Martinelli I, Ruggenenti P, Cetin I, et al. The HAPPY Study Group. Heparin in pregnant women with previous placenta mediated pregnancy complications: a prospective, randomized, multicenter, controlled clinical trial. Blood. 2012;119:3269-3275.
34. Gris JC, Chauleur C, Molinari N, et al. Addition of enoxaparin to aspirin for the secondary prevention of placental vascular complications in women with severe pre-eclampsia. The pilot randomised controlled NOH-PE trial. Thromb Haemost. 2011;106:1053-1061.
35. Gris JC, Chauleur C, Faillie JL, et al. Enoxaparin for the secondary prevention of placental vascular complications in women with abruptio placentae. The pilot randomised controlled NOH-AP trial. Thromb Haemost. 2010;104: 771-779.
36. Rey E, Garneau P, David M, et al. Dalteparin for the prevention of recurrence of placentalmediated complications of pregnancy in women without thrombophilia: a pilot randomized controlled trial. J Thromb Haemost. 2009;7: 58-64.
37. Mello G, Parretti E, Fatini C, et al. Lowmolecular-weight heparin lowers the recurrence rate of preeclampsia and restores the physiological vascular changes in angiotensin-converting enzyme DD women. Hypertension. 2005;45: 86-91.
38. Greer IA, Nelson-Piercy C. Low-molecularweight heparins for thromboprophylaxis and treatment of venous thromboembolism in pregnancy: a systematic review of safety and efficacy. Blood. 2005;106:401-407.